About us
- >
- About us >
- Information >
- Announcement
2024-11-19
Energenesis Biomedical Signs MOU with Taiwan Tanabe Seiyaku Co., Ltd., a subsidiary of Mitsubishi Tanabe Pharma Corporation, Japan, for the Commercialization Rights of F703DFU in Taiwan and Southeast Asia (ASEAN)
Energenesis Biomedical has signed a Memorandum of Understanding (MOU) with Taiwan Tanabe Seiyaku Co., Ltd., (hereinafter Taiwan Tanabe) to establish an exclusive licensing and pharmaceutical manufacturing partnership for ENERGI-F703DFU, a new drug targeting the treatment of diabetic foot ulcers (hereinafter "F703DFU"), across Taiwan and Southeast Asia (ASEAN).